OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 4,153 CSTL derivative securities | OQRO

Home
Insider trades
Castle Biosciences
Officer exercised or converted 4,153 CSTL derivative securities

Insider trades

Insider trade

Officer exercised or converted 4,153 CSTL derivative securities

Traded Oct 1, 2026 · Filed Oct 6, 2026

CSTCastle BiosciencesCSTL

4,153
Shares · @ $3.38

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 1, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 6, 2026

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001628280-26-064912

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Oct 6, 2026, 12:07 AM UTC

Added to OQRO

Oct 7, 2026, 1:51 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CASTLE BIOSCIENCES INC

Issuer CIK

1447362

Ticker

CSTL

Reporting person

Kristen M Oelschlager

Relationship

Officer

Officer title

Chief Operating Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Oct 1, 2026

Transaction code

Shares / units

4,153

Price per share

$3.38

Acquired / disposed

Acquired (A)

Shares owned after

17,509

Ownership form

Direct

Amendment

Footnotes from the filing

These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.

Around the same time

Kristen M Oelschlager (Chief Operating Officer) sold ~$100K of Castle Biosciences

Scheduled in advanceFiled yesterday

Kristen M Oelschlager (Chief Operating Officer) sold ~$49K of Castle Biosciences

Scheduled in advanceFiled yesterday

Kristen M OelschlagerChief Operating Officer

Filed yesterday

4,153Derivative units

Traded Oct 1 · filed 5 days later

Derivative exercise or conversion — not an open-market buy.

More Official record